secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-103997
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Q2 net loss $52.7M, cash $217.6M; advances NMRA-861 Phase 1, obesity lead for NMRA-215
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities of $217.6M as of June 30, 2025; expected to fund operations into 2027.
- Q2 net loss $52.7M vs $58.7M in Q2 2024; R&D expense fell to $38.7M from $48.6M.
- Initiated Phase 1 SAD/MAD study of M4 PAM NMRA-861; data expected Q1 2026.
- Prioritized obesity as lead indication for NLRP3 inhibitor NMRA-215; preclinical DIO data expected in 2025, clinical start Q1 2026.
- Expects up to six clinical data readouts over next 18 months including navacaprant Phase 3 (1H 2026) and NMRA-511 Phase 1b (end 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000095017025103997/0000950170-25-103997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000095017025103997/nmra-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-103997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer